Straits Times Index
3,279.33 -13.80 (-0.42%) Nikkei
37,621.87 -838.21 (-2.18%) Hang Seng
17,251.68 +50.41 (+0.29%) FTSE 100
8,040.38 -4.43 (-0.06%) Bitcoin USD
64,229.36 -2,498.98 (-3.74%) CMC Crypto 200
1,387.31 -36.79 (-2.58%)
Santhera Pharmaceuticals Holding AG (SANN.SW)
| Previous close | 9.65 |
| Open | 9.65 |
| Bid | 9.62 x 0 |
| Ask | 9.46 x 0 |
| Day's range | 9.14 - 9.70 |
| 52-week range | 6.04 - 14.62 |
| Volume | |
| Avg. volume | 23,960 |
| Market cap | 110.476M |
| Beta (5Y monthly) | 0.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.63 |
| Earnings date | 25 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 30.00 |
GlobeNewswireSanthera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on April 25, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT. Details are at the end of this news release. Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May 2023 financial key figures: Revenue from contracts with customers of CHF 103.4 million (2022: CHF 7.5 million) Net result of CHF 54.8 million (2022: CHF -71.1 million) Cash flow from operating
- GlobeNewswire
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA
Pratteln, Switzerland, March 27, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that the China National Medical Products Administration (NMPA) has accepted for priority review the new drug application (NDA) for vamorolone in Duchenne muscular dystrophy (DMD) which was submitted by Sperogenix Therapeutics, Santhera's specialized rare disease partner for China. The Center for Drug Evaluation (CDE) of the Chinese drug authority NMPA accepted the filing and granted priority review for vamorol
- GlobeNewswire
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
AGAMREE® is U.S. FDA approved and now available in the United States for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and olderThis follows the first commercial launch of AGAMREE in Germany in January 2024 by SantheraAGAMREE is the first DMD treatment approved across the U.S., EU and UK Pratteln, Switzerland, March 14, 2024 – Santhera Pharmaceuticals (SIX: SANN) is pleased to note the launch of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystroph
